WO2016126876A3 - Listeria-based adjuvants - Google Patents

Listeria-based adjuvants Download PDF

Info

Publication number
WO2016126876A3
WO2016126876A3 PCT/US2016/016452 US2016016452W WO2016126876A3 WO 2016126876 A3 WO2016126876 A3 WO 2016126876A3 US 2016016452 W US2016016452 W US 2016016452W WO 2016126876 A3 WO2016126876 A3 WO 2016126876A3
Authority
WO
WIPO (PCT)
Prior art keywords
listeria
based adjuvants
methods
disclosure
transplant
Prior art date
Application number
PCT/US2016/016452
Other languages
French (fr)
Other versions
WO2016126876A2 (en
Inventor
Robert Petit
Original Assignee
Advaxis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advaxis, Inc. filed Critical Advaxis, Inc.
Publication of WO2016126876A2 publication Critical patent/WO2016126876A2/en
Publication of WO2016126876A3 publication Critical patent/WO2016126876A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This disclosure provides methods and compositions for using Listeria monocytogenes as an adjuvant for enhancing immune responses in a subject. In certain instances, methods of this disclosure may be useful for subjects receiving a transplant.
PCT/US2016/016452 2015-02-03 2016-02-03 Listeria-based adjuvants WO2016126876A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562111147P 2015-02-03 2015-02-03
US62/111,147 2015-02-03

Publications (2)

Publication Number Publication Date
WO2016126876A2 WO2016126876A2 (en) 2016-08-11
WO2016126876A3 true WO2016126876A3 (en) 2016-10-27

Family

ID=56564870

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/016452 WO2016126876A2 (en) 2015-02-03 2016-02-03 Listeria-based adjuvants

Country Status (1)

Country Link
WO (1) WO2016126876A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
AU2013232291B8 (en) 2012-03-12 2016-07-21 Advaxis, Inc. Suppressor cell function inhibition following listeria vaccine treatment
KR20160130774A (en) 2014-02-18 2016-11-14 어드박시스, 인크. Biomarker directed multi-target immunotherapy
WO2015164121A1 (en) 2014-04-24 2015-10-29 Advaxis, Inc. Recombinant listeria vaccine strains and methods of producing the same
MA41644A (en) 2015-03-03 2018-01-09 Advaxis Inc LISTERIA-BASED COMPOSITIONS INCLUDING A MINIGEN EXPRESSION SYSTEM CODING PEPTIDES, AND METHODS OF USE THEREOF
KR20180107102A (en) 2015-12-16 2018-10-01 그릿스톤 온콜로지, 인코포레이티드 Identification of new antigens, manufacture, and uses
AU2017367642A1 (en) 2016-11-30 2019-05-30 Advaxis, Inc. Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
AU2018336988B2 (en) 2017-09-19 2023-06-22 Advaxis, Inc. Compositions and methods for lyophilization of bacteria or Listeria strains
CN111465989A (en) 2017-10-10 2020-07-28 磨石肿瘤生物技术公司 Identification of neoantigens using hot spots
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. Reducing junction epitope presentation for neoantigens

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALPDOGAN, 0. ET AL.: "Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation.", BLOOD, vol. 105, no. 2, 2005, pages 865 - 873, XP002604499 *
MACIAG, P. C. ET AL.: "The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix.", VACCINE, vol. 27, no. 30, 2009, pages 3975 - 3983, XP026153147 *
ROBACK, J. D.: "Vaccine-enhanced donor lymphocyte infusion (veDLI).", ASH EDUCATION PROGRAM BOOK, vol. 2006, no. 1, 2006, pages 486 - 491, XP055324970 *
SEGGEWISS, R. ET AL.: "Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update.", vol. 115, no. 19, 2010, pages 3861 - 3868, XP055324979 *
ZAKRZEWSKI, J. L. ET AL.: "Adoptive transfer of T- cell precursors enhances T- cell reconstitution after allogeneic hematopoietic stem cell transplantation.", NATURE MEDICINE, vol. 12, no. 9, 2006, pages 1039 - 1047, XP055324976 *

Also Published As

Publication number Publication date
WO2016126876A2 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
WO2016126876A3 (en) Listeria-based adjuvants
HK1255296A1 (en) Crispr/cas-related methods and compositions for improving transplantation
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
WO2012125551A8 (en) Listeria-based adjuvants
WO2016061389A3 (en) Anti-alpha-synuclein antibodies and methods of use
EP3273950A4 (en) Adjuvant compositions and related methods
EP3251131A4 (en) Preservation of strain in iron nitride magnet
IL250818A0 (en) Methods and compositions for enhancing immune responses
EP3176794A4 (en) Rapidly-quenched alloy and preparation method for rare-earth magnet
EP3484509A4 (en) Compositions and methods for flavivirus vaccination
MY191539A (en) Streptococcal vaccine
MY173901A (en) Compositions and methods of enhancing immune responses to enteric pathogens
EP3518976A4 (en) Compositions and methods for improving immune system function
HK1231394A1 (en) Enolase 1 (eno1) compositions and uses thereof 1(eno1)
HK1250637A1 (en) Agents and compositions for eliciting an immune response
WO2016079110A3 (en) Use of enzyme for cleaning
PH12017500120A1 (en) Methods of improving myocardial performance in fontan patients using udenafil compositions
WO2015123493A3 (en) Compositions and methods for modulatuion of immune response
PL3331359T3 (en) Agricultural adjuvant compositions and methods for using such compositions
EP3368547A4 (en) Chimeric rsv, immunogenic compositions, and methods of use
WO2017011769A3 (en) Il-17f-specific capture agents, compositions, and methods of using and making
EP3097420A4 (en) Methods and compositions for immune dis-inhibition
IL265965A (en) Methods and compositions for tusc2 immunotherapy
WO2016049522A3 (en) Compositions comprising ch505 envelopes, and trimers
MX2016009464A (en) Compositions for use in the treatment of allergic conditions.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16747232

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16747232

Country of ref document: EP

Kind code of ref document: A2